Patient preferences regarding treatment options in eosinophilic oesophagitis: swallowed topical steroids overwhelmingly preferred—however, fear of side effects needs to be addressed
- 30 November 2025
- journal article
- Published by BMJ in Frontline Gastroenterology
Abstract
Objective: The approval of budesonide orodispersible tablets and dupilumab has introduced new therapeutic options for the treatment of eosinophilic oesophagitis (EoE). However, there is a shortage of data on perspectives of the affected patients regarding therapeutic interventions. We aimed to assess the beliefs, restrictions and preferences of patients with EoE with respect to medical and dietary treatment options. Design/method: We conducted a web-based survey consisting of 34 questions addressing treatment preferences, including currently available and potentially emerging options, using SurveyMonkey among patients with confirmed diagnosis of EoE in Switzerland, Austria and Germany. Results: 150 patients (64% male; 70.7% with concomitant atopic diseases; 44% previously dilated; 22% with ≥3 sessions) responded. With regard to the routes of administration, one to two times daily swallowed topical corticosteroid (STC) was ranked the highest (89.3% generally preferred STC, and 52.7% preferred STC as single most preferred route within the scenario, including every potentially imaginable route of administration and assuming all options would be equally effective), followed by subcutaneous administration every 4 weeks (62.7%, 22%), peroral systemic steroids (46.7%, 18.7%) and weekly subcutaneous administration (38.7%, 0%). Although one-third did not have reservations against long-term medical therapy, 42% were sceptical about long-term treatment and 65% were afraid of adverse events. Patients with fear of drug-related side events were significantly younger (p=0.001), less often dilated (ever) (p=0.03) and had more often experienced adverse events of any prior therapy (p=0.03). Conclusion: Patients with EoE prefer topical agents over other available routes of administration. Patient education is crucial to address concerns regarding long-term treatment.Keywords
This publication has 21 references indexed in Scilit:
- Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension StudyClinical Gastroenterology and Hepatology, 2024
- Prevalence and Costs of Eosinophilic Esophagitis in the United StatesClinical Gastroenterology and Hepatology, 2024
- Mechanisms and clinical management of eosinophilic oesophagitis: an overviewNature Reviews Gastroenterology & Hepatology, 2022
- Efficacy of Therapy for Eosinophilic Esophagitis in Real-World PracticeClinical Gastroenterology and Hepatology, 2020
- Epidemiology and Natural History of Eosinophilic EsophagitisGastroenterology, 2018
- Barriers to improve physician–patient communication in a primary care setting: perspectives of Chinese physiciansHealth Psychology and Behavioral Medicine, 2016
- Diagnostic Delay in Crohn's Disease Is Associated With a Complicated Disease Course and Increased Operation RateAmerican Journal of Gastroenterology, 2013
- Shared decision making and other variables as correlates of satisfaction with health care decisions in a United States national surveyPatient Education and Counseling, 2012
- Eosinophilic Esophagitis in Children and Adults: A Systematic Review and Consensus Recommendations for Diagnosis and TreatmentGastroenterology, 2007
- Esophageal eosinophilia with dysphagiaDigestive Diseases and Sciences, 1993